Collagen Implant May Improve Local Control of Metastatic Brain Tumors
Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
Investigators are currently assessing the antibody drug conjugate HDP-101 as part of a phase 1/2a study.
Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC
Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.
Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia
Exa-cel displayed MCID-exceeding, sustained mean changes from baseline across various HRQOL-related scores in transfusion-dependent β-thalassemia.
Region-Based Genetic Disorders Affect Cancer Treatment Decisions
In areas that have a higher incidence of genetic conditions, experts across different fields have to collaborate to develop cures and therapies.
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer
Patients with full-thickness or outer full-thickness stromal invasion following surgery had improved PFS when treated with SIB radiotherapy.
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
Enfortumab vedotin plus pembrolizumab before and after surgery improved EFS vs surgery alone in patients with MIBC in the phase 3 EV-303 trial.
Examining the Full Scope of Future Advancements in Radiation Oncology
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.
More Global Expertise and Talent Are Needed to Administer Cell Therapies
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
The Fellow's Playbook: How to Make the Most of Your First Oncology Meeting?
Third-year fellows from Weill Cornell Medicine offer 7 key tips for establishing a foundational understanding of the field at major oncology meetings.
FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma
The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.
Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer Care
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer
The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.
Why is Radiotherapy Not More Accessible as a Cancer Treatment?
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
How Can Cellular Therapies Become More Affordable Across the World?
Those with cancer may be able to get cellular therapies more affordably if countries and health systems adopt decentralized closed-system manufacturing.
Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC
With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.
Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer
The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.
Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer
The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.
AI Partnership May Optimize Standardized Oncologic Radiotherapy Delivery
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Adjuvant Alectinib Exhibits Sustained Survival Benefit in ALK+ NSCLC
Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.
Frontline Immunotherapy Improves OS vs BRAF/MEK Inhibitors in BRAF+ NSCLC
Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer.
FDA Issues CRL for Dasatinib in CML/ALL
Based on the Good Manufacturing Practice observations, the FDA has given a complete response letter for dasatinib for patients with CML/ALL.
Survival Improves With Perioperative Pembrolizumab in Early-Stage NSCLC
Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.
Zanzalintinib Combo Improves Survival in Pretreated Metastatic CRC
Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.
Temab-A Displays Early Efficacy in Locally Advanced/Metastatic PDAC
The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.
Dato-DXd May Be Next SOC in First-Line TNBC
Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.
Which Technology Advancements Have Improved Radiotherapy Care?
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
![Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F55a279b707f0cd71181a5efa8b3d3cd864555701-3002x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].")
